- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00671580
Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection
A Phase II Randomized, Observer-Blind, Multi-Center Study to Evaluate the Safety, Potential Efficacy, and Pharmacokinetics of Two Dosing Regimens of Intravenous PZ-601 and Standard of Care in the Treatment of Complicated Skin and Skin Structure Infections
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
- eStudySite - Sharp Chula Vista
-
Fountain Valley, California, United States, 92708
- Novellus Research Site
-
Long Beach, California, United States, 90806
- Novellus Research Site
-
Oceanside, California, United States, 92056
- eStudySite - Tri-City Medical Center
-
San Jose, California, United States, 95124
- eStudySite - Good Samaritan Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46280
- Infectious Disease Of Indiana, Psc
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Gulf Coast Research, LLC
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- University of Missouri Health Care
-
Kansas City, Missouri, United States, 64108
- Truman Medical Center - Hospital Hill
-
-
Montana
-
Butte, Montana, United States, 59701
- Mercury Street Medical Group
-
-
New Jersey
-
Teaneck, New Jersey, United States, 07666
- Holy Name Hospital Institute for Clinical Research
-
-
Ohio
-
Akron, Ohio, United States, 44304
- Summa Health System
-
Columbus, Ohio, United States, 43215
- Remington-Davis, Inc.
-
-
Pennsylvania
-
Warren, Pennsylvania, United States, 16365
- NewBridge Medical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent provided by the patient
- Males and females ≥ 18 years of age
Diagnosis of complicated skin and skin structure infection defined as infection which meets the following criteria:
- Suspected to be caused by bacterial pathogens, including multi-drug resistant organisms such as MRSA, and
Involves deeper soft tissue and/or require significant surgical intervention such as:
- major abscesses
- infected burn (less than or equal to 20% body surface area)
- traumatic wound infection
- deep/extensive cellulitis
- surgical wound infection
- infected ulcer (with the exception of multiple infected ulcers at distant sites.) Please Note: Patients with multiple sites of skin infection may be enrolled in the study. The most severely affected site or the one most likely to yield a positive culture should be chosen to follow throughout the course of evaluations.
Presents with at least TWO of the following local symptoms:
- Purulent or seropurulent drainage/discharge
- Erythema
- Fluctuance
- Heat/Localized Warmth
- Pain/tenderness to palpation
- Swelling/induration
At least ONE of the following systemic signs of infection
- Increased Temperature (≥100.4ºF/≥38.0ºC) measured orally or its equivalent (note: other methods of obtaining temperature are acceptable)
- WBC (>10,000 cells/mm3)
- Immature neutrophils (>10% band forms regardless of the total peripheral white count)
- Require initial hospitalization with at least 7 days of parenteral therapy for treatment of suspected cSSSI infection
- Ability to obtain a culture and Gram stain of the cSSSI site within 48 hours prior to the initiation of study medication;
Exclusion Criteria:
- Female patients who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study, or who are of child bearing potential and not using an acceptable method of birth control (ie, surgically sterile, intrauterine device, oral contraceptive plus barrier contraceptive, hormone delivery system plus barrier contraceptive or condom in combination with contraceptive cream, jelly or foam)
Received more than 24 hours of systemic antibiotic therapy within 96 hours of initiation of study medication for the current episode of cSSSI, unless:
- there is evidence of clinical failure following at least 48 hours of prior, non-study systemic therapy OR
- there is microbiological evidence of failure (ie, Gram stain reveals WBC and at least one potential pathogen or isolation of an organism resistant to the prior therapy)
- Concomitant conditions requiring antimicrobial therapy that would interfere with the evaluability of the condition under study
- Anticipated need for prolonged antibiotic therapy (ie, >14 days)
- Topical use of antimicrobials (excluding vaginally or topically administered antifungal agents)
- cSSSI known or suspected to be caused by fungal, parasitic or viral infections
cSSSI of the following categories:
- infected diabetic foot ulcers or decubitus ulcer
- multiple infected ulcers at distant sites
- involve an ischemic ulcer due to peripheral vascular disease
- presence of gangrene of any etiology
- Necrotizing fasciitis or gas gangrene
- Infections resulting from human or animal bites (excluding infections secondary to arthropod bites)
- Known or suspected osteomyelitis or septic arthritis
- Superinfected eczema or other chronic medical conditions (eg, atopic dermatitis, hidradentitis suppurativa) characterized by prominent signs of inflammation for an extended period even after successful bacterial eradication
- Patients who have undergone more than two surgical interventions (defined as surgery that cannot be performed at the bedside) for treatment of cSSSI at the time of enrollment
- Patients who are expected to require more than two surgical interventions (defined as surgery that cannot be performed at the bedside) for treatment of cSSSI during the first 48 hours following study enrollment
- Infections complicated by the presence of prosthetic materials that will not be removed such as permanent intracardiac devices or joint replacement prosthesis
- Moderately or severely impaired renal function with known creatinine clearance <50 mL/min (based on the Cockcroft-Gault formula using ideal body weight)
- ALT or AST >3x upper limit of normal or bilirubin >1.5x upper limit of normal (ULN)
- Neutropenia defined as an absolute neutrophil count <500/mm3
- Thrombocytopenia defined as a platelet count <50,000 cells/mm3
- Infection with human immunodeficiency virus and a CD4 count known at the time of enrollment to be <200 cells/mm3 or another Acquired Immune Deficiency Syndrome (AIDS)-defining illness
- Requiring concomitant administration of systemic corticosteroids greater than 40 mg/day of prednisolone (or equivalent)
- Treatment with cancer chemotherapy, radiotherapy, or potent, non-corticosteroid immunosuppressant drugs (eg, cyclosporine, azathioprine, tacrolimus, immune-modulating monoclonal antibody therapy, etc.) within the 3 months prior to study enrollment
- Concomitant therapy with medications known to lower seizure threshold or those patients with a history of seizure disorder
- Concomitant therapy with medications known to be associated with QTc prolongation potential (eg, Class IA and Class III anti-arrhythmic agents)
History or significant cardiac disease defined by the following:
- New York Heart Association (NYHA) Class III or IV heart failure
- History or risk of ventricular arrhythmia (excluding isolated premature ventricular contractions [PVC's] or consecutive PVC's <10 beats), Torsades de Pointes, 2nd or 3rd degree AV block, or QTc interval >470 mm/sec
- History of any hypersensitivity or allergic reaction to beta-lactam drugs such as carbapenems, penicillins, or cephalosporins
- History of any hypersensitivity or allergic reaction to vancomycin or history of Red Man Syndrome
- Any planned medical intervention or personal event that might interfere with the ability to comply with the study requirements
- Any condition that, in the opinion of the principal investigator, would compromise the safety of the patient or the quality of the data
- Life expectancy of less than 3 months from the time of enrollment
- Use of an investigational drug or device (ie, a drug or device without an FDA approved indication) within the previous 30 days
- Prior participation in this protocol
- Unable or unwilling to adhere to the study-specified procedures and restrictions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
PZ-601
|
750 mg
1000 mg
|
Experimental: B
PZ-601
|
750 mg
1000 mg
|
Active Comparator: C
Standard of Care
|
as directed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy parameter is the proportion of patients experiencing clinical response based on improvement or resolution of clinical signs and symptoms of infection in the Clinically Evaluable population at the Test of Cure visit.
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Response in the Clinically Evaluable (CE) population at the End of Treatment (EOT) visit
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Clinical Response in the Intent-to-Treat (ITT), Microbiological ITT (mITT), and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Clinical Response in the Intent-to-Treat (ITT), Microbiological ITT (mITT), and Microbiologically Evaluable (ME) populations at the End of Treatment (EOT) visit
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
By-pathogen and by-patient Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
By-pathogen and by-patient Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the End of Treatment (EOT) visit
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Overall combined Clinical and Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Overall combined Clinical and Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the End of Therapy (EOT) visit
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PZ-601-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Infections
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedSkin Infections, BacterialUnited States
-
GlaxoSmithKlineCompletedSkin Infections, BacterialNetherlands, Costa Rica, Germany, Mexico, Canada, India, Poland, South Africa, France, Peru
-
GlaxoSmithKlineCompletedImpetigoIndia, Mexico, Netherlands, Italy, Peru
-
Ferrer Internacional S.A.Completed
-
Philippine Dermatological SocietySt. Luke's Medical CenterUnknown
-
NovaBay Pharmaceuticals, Inc.Novum Pharmaceutical Research Services; International Dermatology Research,...Completed
-
UNION therapeuticsCompleted
-
Ferrer Internacional S.A.CompletedEfficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoImpetigoGermany, South Africa
Clinical Trials on PZ-601
-
Joanne Kurtzberg, MDAldagenWithdrawnLysosomal Storage Diseases | Inborn Errors of MetabolismUnited States
-
ADC Therapeutics S.A.TerminatedAdvanced Solid TumorsUnited States
-
C.B. Fleet Company, Inc.CompletedBowel Cleansing Prior to ColonoscopyUnited States
-
Borstkanker Onderzoek GroepRoche Pharma AG; BOOG Study CenterActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
-
Motric BioRecruitingStroke | Multiple Sclerosis | Cerebral Palsy | Spinal Cord Injuries | Dystonia | Muscle Spasticity | Hereditary Spastic Paraplegia | Hypertonia, MuscleUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
TransMolecularUnknownAstrocytoma | Glioblastoma Multiforme | Malignant Glioma | GBM | OligodendrogliomaUnited States
-
Erasca, Inc.Active, not recruitingAdvanced or Metastatic Solid TumorsUnited States
-
Tufts Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); Sinai Hospital of BaltimoreCompletedVascular Disease | Coronary Artery Disease Risk Factors MultipleUnited States